Response to the Letter: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or Zoledronic Acid.
Colorado Center for Bone Research (P.D.M.), Lakewood, Colorado; Amgen Inc. (N.P., R.B.W.), Thousand Oaks, California; and San Francisco Coordinating Center (S.R.C.), CPMC Research Institute, San Francisco, California.
Paul D
PD
Miller
Colorado Center for Bone Research (P.D.M.), Lakewood, Colorado; Amgen Inc. (N.P., R.B.W.), Thousand Oaks, California; and San Francisco Coordinating Center (S.R.C.), CPMC Research Institute, San Francisco, California.
Nico
N
Pannacciulli
Colorado Center for Bone Research (P.D.M.), Lakewood, Colorado; Amgen Inc. (N.P., R.B.W.), Thousand Oaks, California; and San Francisco Coordinating Center (S.R.C.), CPMC Research Institute, San Francisco, California.
Rachel B
RB
Wagman
Colorado Center for Bone Research (P.D.M.), Lakewood, Colorado; Amgen Inc. (N.P., R.B.W.), Thousand Oaks, California; and San Francisco Coordinating Center (S.R.C.), CPMC Research Institute, San Francisco, California.
Steven R
SR
Cummings
D015519:Bone Density; D050071:Bone Density Conservation Agents; D000069448:Denosumab; D004164:Diphosphonates; D006801:Humans; D007093:Imidazoles; D008903:Minerals; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D008903:Minerals; D000069448:Denosumab; D000077211:Zoledronic Acid